ImmunityBio Reports 700% Revenue Growth, Expands Anktiva to 33 Countries and Lung Cancer
ImmunityBio announced $113 million in net product revenue for Anktiva in 2025, a 700% year-over-year increase, while expanding regulatory authorization to 33 countries and securing first approval for lung cancer treatment in Saudi Arabia.